UNIVERSITAS
GADJAH MADA

Polimorfisme MDM2 SNP309 T>G; Studi Risiko Kanker Payudara Onset Dini
ALVIN SANTOSO KALIM, Dra. Dewajani Purnomosari, M.Si, Ph.D; dr. Artanto Wahyono, Sp.B
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Daftar Pustaka

Aebi S, Davidson T, Gruber G, Cardoso F. Primary breast cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology 2011(22):12-24

Agrawal A, Yang J, Murphy RF, Agrawal DK, Regulation of the p14ARG-Mdm2-p53 pathway : an overview in breast cancer. Exp Mol Pathol 2006 (81):115-122

Aguas F, Martins A, Gomes TP, de Sousa M, Silva DP. Portuguese Menopause Society and Portuguese Gynaecology Society. Prophylaxis approach to a-symptomatic post-menopausal women: Breast cancer. Maturitas.2005;52(Suppl 1):S23-31

American Cancer Society, 2009, Breast cancer facts and figures 2009-2010, American Cancer Society, Atlanta.

American Cancer Society, 2016, Breast Cancer, American Cancer Society, Atlanta

American Joint Committee on Cancer, 2009, ed. 7, American Cancer Society

Anders CK et al., Breast Cancer Before Age 40 Years, Semin Oncol, 2009 June ; 36(3): 237–249

Assi HA et al., Epidemiology and prognosis of breast cancer in young woman, J Thorac Dis 2013;5(S1):S2-S8

Association of Breast Surgery at Baso 2009.Surgical guidelines for the management of breast cancer. Eur J Surg Oncol 2009; 35 Suppl 1: 1–22.

Beggs AD, Hodgson SV, Genomic and breast cancer: the different levels of inherited susceptibility, European Journal of Human Genetics, 2009 (17) : 855-856

Bennet LB, Taurog JD, Bowcock AM.Hereditary breast cancer genes. In: Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics (Bowcock AM, ed). Totowa, NJ:Humana Press, 1999;199–224. 17. Katsama A, Sourvinos G, Zachos G, Spandid

UNIVERSITAS
GADJAH MADA
Polimorfisme MDM2 SNP309 T>G; Studi Risiko Kanker Payudara Onset Dini
ALVIN SANTOSO KALIM, Dra. Dewajani Purnomosari, M.Si, Ph.D; dr. Artanto Wahyono, Sp.B
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Bond GL, et al., A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humas, Cell2004, 119(5):591-602

Bond, GL et al,MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 2006 , 66, 5104–5110.

Bougeard G, Baert-Desurmont S, Tournier I, *et al*: Impact of the *MDM2 SNP309 T>G* and *TP53* Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2006(43): 531-533

Bray F, Ren JS, Masuyer E, Ferlay J. 2013. Global estimates of cancer prevalence for 27 sites in the adult population in 2008.*Int J Cancer*, 132(5):1133–1145

Brekman et al., A p53-independent role of Mdm2 in estrogenmediated activation of breast cancer cell proliferation, Breast Cancer Research, 2011 (3):1-14

Brennan M et al., Breast cancer in young women. 2005;34 (10) 851 - 855

Bueso-Ramos CE, Manshouri T, Haidar MA, et al., 1996, Abnormal expression of MDM-2 in breast carcinomas, Breast Cancer Res Treat 37:176-188

Cahilly-Snyder, L, Yang-Feng, T, Francke, U, George Dl, Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line, Somatic Cell Mol, Genet., 13 : 235-244, 1987

Campbell IG, Eccles DM, Choong DY, 2006, No association of the MDM2 SNP309 T>G polymmorphism with the risk of breast or ovarian cancer, Cancer Lett 240:195-197

Colleoni M et al., Very young women (< 35 years) with operable breast cancer : features of disease presentation. Annals of Oncology.2002 ;13 : 273 - 279

Cox DG, et al., The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses' health studies, Cacncer Causes Control (2007), 18:621-625

Depkes RI, 2009, Buku Saku Pencegahan Kanker Mulut Rahim dan Kanker Payudara

UNIVERSITAS
GADJAH MADA
Polimorfisme MDM2 SNP309 T>G; Studi Risiko Kanker Payudara Onset Dini
ALVIN SANTOSO KALIM, Dra. Dewajani Purnomosari, M.Si, Ph.D; dr. Artanto Wahyono, Sp.B
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Dorland, W. N. (2007). *Kamus Kedokteran Dorland Edisi 31*. Jakarta: Penerbit Buku Kedokteran EGC.

Dumitrescu RG, Cotarla I. Understanding breast cancer risk - where do we stand in 2005? J Cell Mol Med. 2005;9:208–21

Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087–2106.

Economopoulos KP, Sergentanis TN, 2010, Differential effects of MDM2 SNP 309 polymorphism on breast cancer risk along with race : a meta analysis, Breast Cancer Res Treat 120(1):211-216

Ellis, IO, et al, 2003, Invasive breast carcinoma, In : Tavassoli FA, Devilee P(Ed.) : Tumours of the breast and female genital organ pp: 13-59, IARC Press, Lyon

Farkharzadeh, SS, Trusko, SP, and George DL, Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J., 10 : 1565-1569, 1991

Freedman DA, Wu L, Levine AJ (1999) Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55:96–107

Gabriel CA, Domchek SM, Breast Cancer in Young Women. Breast Cancer Research. 2010;12 :212

Gao et al., Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls, Ther Clin Risk Manag. 2014; 10: 269–277.

GLOBOCAN 2012, IARC. United States Census Bureau, International Data Base country population

Hankey BF, Miller B, Curtis R, Kosary C. Trends Breast Cancer in Younger Women in Contrast to Older Women. Journal of the National Cancer Institute Monograph. 1994;16 : 7 - 14

Henderson BE, Feigelson HS. Hormonal carcinogenesis.Carcinogenesis 21:427–433 (2000)

Hussain SP, Hollstein MH, Harris CC. p53 tumor suppressor gene: at the crossroads of molecular

UNIVERSITAS
GADJAH MADA
Polimorfisme MDM2 SNP309 T>G; Studi Risiko Kanker Payudara Onset Dini
ALVIN SANTOSO KALIM, Dra. Dewajani Purnomosari, M.Si, Ph.D; dr. Artanto Wahyono, Sp.B
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

carcinogenesis, molecular epidemiology, and human risk assessment. Ann N Y Acad Sci. 2000;919:79–85

Keegan THM et al., Impact of breast cancer subtypes on 3 – year survival among adolescent and young adult women. Breast Cancer Research. 2013;15 : R95

Kinyamu, HK et al, Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol. Cell. Biol. 2003, 23 , 5867–5881.

Knappskog S, Lonning PE, Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk, Transcription 2011, 2(5):207-210

Lang A, Wegman PP, Wingren S, 2009, The significance of MDM2 SNP309 T>G and p53 Arg72Pro in young women with breast cancer, Oncology Reports 22 : 575-579

Lum SS, et al., MDM2 SNP309 T>G G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population, Carcinogenesis, 2008, 29(4) : 754-761

Ma H et al., (2006) Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett., 240, 261–267.

Manfredi JJ, The Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor, Genes and Development 2010 (24):1580–1589

Marchetti A, Buttitta F, Girlando S, et al., MDM2 genes alterations and MDM2 protein expression in breast carcinomas, J Pathol 1995;175:31-38

Milliani de Marval PL, Zhang Y, The RP-Mdm2-p53 pathway and tumorigenesis, Oncotarget 2011, 2(3):234-238

Moll UM, Petrenko O, The MDM2-p53 intetaction, Mol Cancer Res 2003, 1(14):1001-1008

Momand J, Zambetti GP, Olson DC, George D, and Levine AJ, The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation, Cell, 69:1237-1245, 1992

Nusbaum R, Isaacs C: Management updates for women with a BRCA1 or BRCA2 mutation, Mol Diagn Ther 2007 (11): 133 – 144.

UNIVERSITAS
GADJAH MADA
Polimorfisme MDM2 SNP309 T>G; Studi Risiko Kanker Payudara Onset Dini
ALVIN SANTOSO KALIM, Dra. Dewajani Purnomosari, M.Si, Ph.D; dr. Artanto Wahyono, Sp.B
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Okumura N, Saji S, Eguchi H, et al., 2002, Estradiol stabilizes p53 protein in breas cancer cell line, MCF-7, Jpn J Cancer Res, 93(8):867-73

Partridge AH et al., Breast Cancer in Young Women.Disease of the Breast Fourth Edition. 2009;92 : 1073 – 1080

Petenkaya et al., Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk, Anticancer Res 2006, 26(6C):4957-4977

Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets. 2005;5:27–41

Rosenthal TC, Puck SM, Screening for Genetic Risk of Breast Cancer (*American Family Physician* January 01,1999, http://www.aafp.org/afp/990101ap/99.html)

Ruijs MW et al., The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes, Eur Jour of Hum Gen 2007 (15):110-114

Russell RC, Bulstrode CJ, Williams NS.Bailey and Love's short practice of surgery. In: Williams N, Bulstrode C, O'Connell, editors. Chapter on Breast Cancer. 23rd ed. London: Arnold; 2000.

Sun YF, Leu JD, Chen SM, Lin IF, Lee YJ. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer, BMC Cancer, 2009;9:13

Surveillance Epidemiology and End Results (SEER). SEER Stat Fact Sheets: Breast. Available at http://seer.cancer.gov/statfacts/html/breast.html#incidence-mortality. Accessed March 19, 2014

Thapa B et al., Breast Cancer in Young Women from a Low Risk Population in Nepal. Asian Pasific Journal of Cancer Prevention. 2013;14 : 5095 - 5099

Wasielewski,M. et al. MDM2 SNP309 T>G accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res. Treat 2007(104) 153–157.

WHO, 2008, World Health Statistiks 200